The fastest-growing and largest of the 20 sized Pharmaceuticals markets in Germany, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $1.4 Bn | $10.8 Bn | 23.1% | – |
| 2 | Cell Based Immunotherapy | $608 Mn | $4.2 Bn | 21.2% | – |
| 3 | Cannabidiol (CBD) | $807 Mn | $3.3 Bn | 15% | – |
| 4 | Cannabis | $1.2 Bn | $3.8 Bn | 11.7% | – |
| 5 | Atopic Dermatitis Drugs | $411 Mn | $1.1 Bn | 10.4% | – |
| 6 | Oncology/Cancer Drugs | $6.5 Bn | $12.3 Bn | 6.6% | – |
| 7 | Anti-Aging | $3.2 Bn | $5.9 Bn | 6.3% | – |
| 8 | Diabetes Management | $2.9 Bn | $4.8 Bn | 5.3% | – |
| 9 | Alzheimer Drugs | $183 Mn | $299 Mn | 5% | – |
| 10 | Contraceptives Drugs | $922 Mn | $1.5 Bn | 5% | – |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $6.5 Bn | $12.3 Bn | 6.6% | – |
| 2 | Anti-Aging | $3.2 Bn | $5.9 Bn | 6.3% | – |
| 3 | Diabetes Management | $2.9 Bn | $4.8 Bn | 5.3% | – |
| 4 | Gastrointestinal Drugs | $2 Bn | $2.6 Bn | 2.8% | – |
| 5 | Asthma & COPD Drugs | $1.8 Bn | $2.3 Bn | 2.2% | – |
| 6 | Biosimilars | $1.4 Bn | $10.8 Bn | 23.1% | – |
| 7 | Cannabis | $1.2 Bn | $3.8 Bn | 11.7% | – |
| 8 | HIV Drugs | $1.1 Bn | $1.6 Bn | 4% | – |
| 9 | Contraceptives Drugs | $922 Mn | $1.5 Bn | 5% | – |
| 10 | Cancer Supportive Care Drugs | $908 Mn | $1.2 Bn | 2.9% | – |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 23.1% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (21.2%).
Oncology/Cancer Drugs is the largest, worth about $6.5 Bn in 2023 and $12.3 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.